share_log

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Strong Profits May Be Masking Some Underlying Issues

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Strong Profits May Be Masking Some Underlying Issues

京新药业 (SZSE:002020) 强劲的利润可能掩盖了一些潜在问题
Simply Wall St ·  11/01 06:15

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) healthy profit numbers didn't contain any surprises for investors. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

浙江京新药业(SZSE:002020)的盈利数字对投资者并没有什么意外。我们认为股东们已经注意到了一些超出法定盈利数字的令人担忧因素。

big
SZSE:002020 Earnings and Revenue History October 31st 2024
SZSE:002020 盈利和营业收入历史数据为2024年10月31日

How Do Unusual Items Influence Profit?

非常规项目如何影响利润?

Importantly, our data indicates that Zhejiang Jingxin Pharmaceutical's profit received a boost of CN¥119m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If Zhejiang Jingxin Pharmaceutical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我们的数据显示,浙江京新药业的盈利在过去一年中由于飞凡项目获得了CN¥11900万的提升。虽然我们乐于看到利润增长,但当飞凡项目做出重大贡献时,我们往往会更加谨慎。当我们分析全球上市公司的绝大部分时,我们发现重大的飞凡项目通常不会重复出现。这一点并不奇怪,考虑到其名称。如果浙江京新药业不再看到该贡献重复,那么其他一切不变的情况下,我们预计其利润在当前年度会下降。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

这可能会让您想知道分析师对未来盈利能力的预测。幸运的是,您可以单击此处查看基于其估计的未来盈利能力的互动图表。

Our Take On Zhejiang Jingxin Pharmaceutical's Profit Performance

我们对浙江京新药业的盈利表现的看法

We'd posit that Zhejiang Jingxin Pharmaceutical's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Zhejiang Jingxin Pharmaceutical's statutory profits are better than its underlying earnings power. The good news is that, its earnings per share increased by 9.1% in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. While it's really important to consider how well a company's statutory earnings represent its true earnings power, it's also worth taking a look at what analysts are forecasting for the future. At Simply Wall St, we have analyst estimates which you can view by clicking here.

我们认为京新药业的法定收益并不是对持续生产力的清晰衡量,因为存在大额飞凡项目。因此,我们认为京新药业的法定利润可能比其潜在盈利能力更好。好消息是,其每股收益在过去一年增长了9.1%。归根结底,如果您想正确了解公司,重要的是考虑不止上述因素。虽然重要的是考虑公司的法定收益如何代表其真实盈利能力,但也值得看看分析师对未来的预测。在Simply Wall St,我们有分析师预测,您可以点击这里查看。

Today we've zoomed in on a single data point to better understand the nature of Zhejiang Jingxin Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

今天,我们将焦点放在一个单一数据点上,以更好地了解京新药业利润的性质。但有很多其他方法可以帮助您了解一家公司。例如,许多人将股本回报率视为有利的业务经济指标,而其他人则喜欢‘跟随资金’,搜索内部人员正在买入的股票。虽然您可能需要进行一点研究,但您可能会发现这个免费收集的公司拥有高股本回报率,或者这个拥有重要内部持股的股票清单很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发